MIRA Pharmaceuticals Advances Ketamir-2 Clinical Trials
MIRA Pharmaceuticals has initiated the multiple ascending dose phase of its Phase 1 clinical trial for Ketamir-2, aimed at treating chemotherapy-induced peripheral neuropathy (CIPN). This is notable as there are no FDA-approved treatments for CIPN. Ketamir-2 has shown promising preclinical results and may qualify for FDA Fast Track designation. MIRA focuses on developing therapies for unmet medical needs, with Ketamir-2 being an oral analog of ketamine for neuropathic pain. Current market cap is $27.65M with a buy signal in technical sentiment.
MIRA Pharmaceuticals, Inc. ( (MIRA) ) has provided an update.
MIRA Pharmaceuticals has initiated the multiple ascending dose (MAD) phase of its Phase 1 clinical trial for Ketamir-2, targeting chemotherapy-induced peripheral neuropathy (CIPN) as the lead indication for Phase 2a evaluation. This development is significant as there are currently no FDA-approved treatments for CIPN, and Ketamir-2 has shown promising preclinical results, potentially positioning it as a non-opioid therapy that could qualify for FDA Fast Track designation.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing novel therapies for conditions with significant unmet medical needs. The company’s primary product is Ketamir-2, an oral analog of ketamine designed to treat neuropathic pain without the limitations of traditional ketamine use.
Average Trading Volume: 3,101,092
Technical Sentiment Signal: Buy
Current Market Cap: $27.65M
Learn more about MIRA stock on TipRanks’ Stock Analysis page.
